<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909818</url>
  </required_header>
  <id_info>
    <org_study_id>DBCG hypo protocol</org_study_id>
    <secondary_id>CIRRO IP030209</secondary_id>
    <secondary_id>The Danish Cancer Society</secondary_id>
    <nct_id>NCT00909818</nct_id>
  </id_info>
  <brief_title>Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients</brief_title>
  <official_title>Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients: a Randomized Phase II Trial, CIRRO (The Lundbeck Foundation Center for International Research in Radiation Oncology)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Breast Cancer Cooperative Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the difference in late radiation morbidity
      between hypofractionated and standard fractionated breast irradiation given to women operated
      with breast conservation for early breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The randomization is between 50 Gy/25 fractions, 2.0 Gy per fraction, 5 fractions weekly, and
      40 Gy/15 fractions, 2.67 Gy per fraction, 5 fractions weekly. The primary endpoint is late
      radiation morbidity; secondly, we want to investigate the frequency of local recurrences, and
      try to establish a genetic risk profile for development of late radiation morbidity.

      The hypothesis is that women operated with breast conserving strategy for early breast cancer
      can be offered moderately hypofractionated radiotherapy without developing more late
      radiation morbidity compared to standard fractionated radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 2 or 3 fibrosis 3 years after radiotherapy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any other late morbidity after adjuvant radiotherapy, genetic risk profile for late morbidity, recurrence/survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">976</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Carcinoma in Situ of the Breast</condition>
  <arm_group>
    <arm_group_label>standard fractionated radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypofractionated radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypofractionated radiotherapy 40 Gy/15 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard fractionated radiotherapy</intervention_name>
    <description>standard fractionated radiotherapy 50 Gy/25 fractions</description>
    <arm_group_label>standard fractionated radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiotherapy</intervention_name>
    <description>hypofractionated radiotherapy 40 Gy/15 fractions</description>
    <arm_group_label>hypofractionated radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  operated with breast conserving strategy for:

               1. invasive breast cancer, pT1-2, pN0-1mi, M0 OR

               2. carcinoma in situ of the breast

        Exclusion Criteria:

          -  previous radiation of the breast/thorax

          -  breast implants

          -  pregnant/lactating

          -  comorbidity which may hinder the patient in completing the therapy and complete follow
             up for 10 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Stenbygaard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aalborg Universitetshospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Birgitte Offersen, MD, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Jakobsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mette H Nielsen, MD, phd</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Birgitte Offersen, MD, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mechthild Krause, M.D., Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic Carl Gustav Carus Dresden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Schreiber, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Praxis für Strahlentherapie am Klinikum Dresden-Friedrichstadt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingvil Mjaaland, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Helse Stavanger HF, Sorlandet Sykehus HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Unn-Miriam Kasti, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Kristiansand Sykehus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Danish Breast Cancer Cooperative Group</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100 Ø</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2009</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Breast Cancer Cooperative Group</investigator_affiliation>
    <investigator_full_name>Birgitte Offersen</investigator_full_name>
    <investigator_title>M.D., ph.d., associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

